Title |
Expression of functional toll like receptor 4 in estrogen receptor/progesterone receptor-negative breast cancer
|
---|---|
Published in |
Breast Cancer Research, September 2015
|
DOI | 10.1186/s13058-015-0640-x |
Pubmed ID | |
Authors |
Meliha Mehmeti, Roni Allaoui, Caroline Bergenfelz, Lao H. Saal, Stephen P. Ethier, Martin E. Johansson, Karin Jirström, Karin Leandersson |
Abstract |
Toll-like receptors (TLRs) are a family of pattern recognition receptors that are expressed on cells of the innate immune system. The ligands can be pathogen derived (pathogen associated molecular patterns; PAMPs) or endogenous (damage associated molecular patters; DAMPs) that when bound induces activation of nuclear factor kappa B (NF-κB) and transcription of pro-inflammatory genes. TLRs have also been discovered in various malignant cell types, but with unknown function. In this study we performed a detailed analysis of TLR and co-receptor expression pattern and function in breast cancer. Expression patterns were examined using real-time quantitative polymerase chain reaction (RT-qPCR) and immunohistochemistry (IHC) on three estrogen receptor-positive (ER(+)) and four estrogen receptor/progesterone receptor-negative (ER(-)/PR(-); ER/PR-negative) breast cancer cell lines, and a breast cancer cohort consisting of 144 primary breast cancer samples. The function was investigated using in vitro assays comprising PAMP/DAMP-stimulation, downstream signaling and TLR-silencing experiments. We found that TLR4 was expressed in a biologically active form and responded to both PAMPs and DAMPs primarily in ER/PR-negative breast cancers. Stimulation of TLR2/4 in vitro induced expression of pro-inflammatory genes and a gene expression analysis of primary breast cancers showed a strong correlation between TLR4 expression and expression of pro-inflammatory mediators. In line with this, TLR4 protein expression correlated with a decreased survival. These findings suggest that TLR4 is expressed in a functional form in ER/PR-negative breast cancers. Studies regarding TLR4-antagonist therapies should be focusing on ER/PR-negative breast cancer particularly. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Germany | 1 | 2% |
Unknown | 57 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 15 | 26% |
Student > Ph. D. Student | 12 | 21% |
Researcher | 5 | 9% |
Student > Bachelor | 4 | 7% |
Student > Doctoral Student | 4 | 7% |
Other | 7 | 12% |
Unknown | 11 | 19% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 11 | 19% |
Agricultural and Biological Sciences | 11 | 19% |
Medicine and Dentistry | 10 | 17% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 7% |
Immunology and Microbiology | 3 | 5% |
Other | 5 | 9% |
Unknown | 14 | 24% |